Exon-skipping therapies for Duchenne muscular dystrophy
In separate trials, investigators reported promising new data on two exon-skipping therapies for Duchenne muscular dystrophy (DMD), eteplirsen and drisapersen. In this video, Neurology Today Editor-in-chief Steven P. Ringel, MD, and Neurology Today Associate Editor Robert G. Holloway Jr., MD, MPH, comment on these results and what they may mean for the DMD community. Read the full story in the June 19 issue of Neurology Today. See the AAN Annual Meeting abstract for more information on eteplirsen: http://bit.ly/eteplirsen.